INSM 163.54 ▲ 1.34% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Insmed

    NASDAQ: INSM · Real-Time Price · USD
    163.54
    2.16 (1.34%)
    At close: Oct 15, 2025, 3:59 PM
    163.54
    0.00%
    After-hours: Oct 15, 2025, 04:10 PM EDT
    1.34%
    Bid 158
    Market Cap 34.57B
    Revenue (ttm) 398.11M
    Net Income (ttm) -1.03B
    EPS (ttm) -5.67
    PE Ratio (ttm) -28.84
    Forward PE -46.31
    Analyst Strong Buy
    Dividends n/a
    Ask 166.65
    Volume 1,856,264
    Avg. Volume (20D) 2,451,429
    Open 162.20
    Previous Close 161.38
    Day's Range 161.65 - 165.76
    52-Week Range 60.40 - 166.44
    Beta 1.03
    Ex-Dividend Date n/a

    About INSM

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol INSM
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for INSM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Insmed is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    +3.97%
    Insmed shares are trading higher after Stifel and ... Unlock content with Pro Subscription
    2 months ago
    +8.07%
    Insmed shares are trading higher after the company announced it received FDA approval for BRINSUPRI.
    news image

    2 weeks ago · seekingalpha.com

    Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality

    Insmed remains a compelling biotech trade after Brinsupri's FDA approval for NCFB, with strong de-risking and significant market potential. Brinsupri's aggressive pricing and broad label could drive p...

    news image

    1 month ago · seekingalpha.com

    Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

    Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call ...

    news image

    1 month ago · seekingalpha.com

    Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

    Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Partici...

    news image

    1 month ago · benzinga.com

    Lung Disease-Focused Insmed 'Must-Own' Name For Investors

    William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

    1 month ago · youtube.com

    Josh Brown's Best Stocks in the Market: Insmed

    Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.

    news image

    2 months ago · https://thefly.com

    Insmed price target raised to $145 from $121 at Stifel

    Stifel raised the firm's price target on Insmed to $145 from $121 and keeps a Buy rating on the shares following FDA's recent approval of Brinsupri as the first approved therapy for treatment of non-C...

    2 months ago · youtube.com

    Insmed CEO on what's next for company after FDA greenlights lung disease drug

    Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.

    news image

    2 months ago · benzinga.com

    FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis ...

    news image

    2 months ago · reuters.com

    US FDA approves Insmed's lung disease drug

    The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.

    news image

    2 months ago · zacks.com

    Don't Overlook Insmed (INSM) International Revenue Trends While Assessing the Stock

    Explore Insmed's (INSM) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

    Add to Watchlist